Journal article
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
- Abstract:
-
Background:
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrexate withdrawal.
Methods:
Expand abstract
OPAL Balance was an open-label, long-term extension study of tofacitinib in patients with psoriatic arthritis who participated in the OPAL Broaden and OPAL Bey...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 486.5KB, Terms of use)
-
- Publisher copy:
- 10.1016/S2665-9913(20)30339-8
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Rheumatology More from this journal
- Volume:
- 3
- Issue:
- 1
- Pages:
- e28-e39
- Publication date:
- 2020-11-16
- Acceptance date:
- 2020-08-24
- DOI:
- EISSN:
-
2665-9913
- Language:
-
English
- Keywords:
- Pubs id:
-
1133215
- Local pid:
-
pubs:1133215
- Deposit date:
-
2020-09-22
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2020
- Rights statement:
- © 2020 Elsevier Ltd. All rights reserved.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/S2665-9913(20)30339-8
If you are the owner of this record, you can report an update to it here: Report update to this record